• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Mologen (Group)

MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase. The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200). *

 

	Start	1997-01-01 existent
	Industry	BIOTECH
	Industry 2	MIDGE® technology (Mologen)
	Person	Söhngen, Mariola (Mologen 201511–201810 CEO before Paion 2000–201510 CMO + Co-Founder LEFT 11/18)
	Person 2	Miller, Walter (Mologen 201604– CFO before Nuvisan Gmbh + Santhera Pharmaceuticals)
	Region	Berlin
	Country	Germany
	Street	30 Fabeckstr.
	City	14195 Berlin
	Tel	+49-30-841788-0
	Fax	+49-30-841788-50
		Address record changed: 2008-12-07
Basic data	Employees	B: 11 to 50 (2017-06-30)
	Currency	EUR
	Annual sales	74,000 (revenues (2016) 2016-12-31)
	Profit	-21,003,000 (2016-12-31)
	Cash	14,200,000 (2016-12-31)
		* Document for �About Section�: Mologen AG. (7/10/12). "Press Release: Mologen AG Capital Increase. Proceeds of 22 Million EUR".
		Record changed: 2017-08-15

Advertisement

More documents for Mologen (Group)

• [1] Mologen AG. (4/20/18). "Press Release: Chief Executive Officer of Mologen AG Will Not Extend Executive Board Mandate Expiring in October 2018 (Ad-hoc News)". Berlin....
• [2] Mologen AG. (3/14/18). "Press Release: Successful Capital Increase with Gross Proceeds of €4.99 Million [Not for release, publication or distribution in or into United States, Australia, Canada or Japan, or any other jurisditcion in which unlawful]". Ber...
• [3] Mologen AG. (8/25/17). "Press Release: Mologen AG and Chinese iPharma Ltd. Signed Binding Term Sheet for a Collaboration Regarding the Development, Manufacture and Commercialization of Lefitolimod in China and a Potential Co-development"....
• [4] Mologen AG. (8/10/17). "Press Release: Important Milestones Achieved in Clinical Trials during the First Half 2017". Berlin....
• [5] Mologen AG. (8/9/17). "Press Release: Results of the Extension Phase of the Exploratory Phase Ib/IIa Study in HIV"....
• [6] Mologen AG. (4/24/17). "Press Release: Positive Subgroup Results of the Exploratory Phase II IMPULSE Study of Lefitolimod in Extensive-disease Small-cell Lung Cancer (SCLC)"....
• [7] Mologen AG. (2/17/17). "Press Release: Mologen to Present at ASCO-SITC Clinical Immuno-Oncology Symposium 2017"....
• [8] Mologen AG. (2/16/17). "Press Release: New Positive Data on Lefitolimod in HIV"....
• [9] Mologen AG. (2/13/17). "Press Release: Dr Matthias Baumann MD Appointed as New Chief Medical Officer"....
• [10] Mologen AG. (1/23/17). "Press Release: Combination Data of TLR9 Agonist Lefitolimod with Checkpoint Inhibitors in Preclinical Tumor Models"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2018. Made in Germany.